Addex Therapeutics announced that the research term of its collaboration agreement with Indivior for the discovery of novel oral gamma-aminobutyric acid subtype B, or GABAB, positive allosteric modulator, or PAM, drug candidates for the treatment of substance use disorder has been extended until June 30, 2023. As part of the amended agreement, Indivior will pay Addex an additional $1M to cover additional research activities during this extended period. Addex retains exclusive rights to develop its own independent GABAB PAM program and is advancing compounds in Charcot-Marie-Tooth type 1A neuropathy, chronic cough and pain.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly